Skip to main content
Fig. 3 | Molecular Brain

Fig. 3

From: Aβ42 treatment of the brain side reduced the level of flotillin from endothelial cells on the blood side via FGF-2 signaling in a blood–brain barrier model

Fig. 3

The cellular and secreted FGF-2 levels were decreased in astrocytes when Aβ42 was added into the brain side. A Western blot analysis of intracellular FGF-2. B Quantification of the FGF-2 protein levels normalized to α-tubulin, and expressed as values relative to the control. Statistical significance was calculated using one-way ANOVA and the Tukey test (*p < 0.05). Data are shown as the mean ± SD (n = 3). C Secreted FGF-2 in the brain side was measured using FGF-2 ELISA kits. Statistical significance was calculated using one-way ANOVA and the Tukey test (*p < 0.05). Data are shown as the mean ± SD (n = 3). The Aβ42 treatment-induced decrease in the FGF-2 levels regulated the phosphorylation levels of FGFR1 in iBMECs. D Protein levels were determined by western blotting and quantified by densitometry. E Quantification of phosphorylated (p-) FGFR1 levels normalized to Flg/FGFR1 levels, and expressed as values relative to the control. Statistical significance was calculated using one-way ANOVA and the Tukey test (**p < 0.01). Data are shown as the mean ± SD (n = 3)

Back to article page

Molecular Brain

ISSN: 1756-6606